FDA approval is the single biggest milestone for a small drug developer — it converts years of research into an actual sellable product with real revenue ahead. Pancreatic cancer has very few effective treatment options, so a targeted once-daily pill addr

Verdict: a real catalyst, but wait for the dip to actually print

The bull case rests on fact, not hope: per the CNBC piece from August 26, Revolution Medicines just received FDA approval for its targeted pancreatic cancer drug, and the balance sheet — roughly $2.1B in current assets against $290M in current liabilities, with no meaningful debt — gives it an unusually long runway to fund the launch. The strongest argument against is that free cash flow was minus $914M in fiscal 2025 and minus $745M already in the first half of 2026, with zero product revenue, so the stock stays hostage to financing and launch-execution news for years. Meanwhile the setup itself has never fired: across 1,235 evaluated daily bars the simultaneous entry alignment did not print, and the requested bounded parameter search exceeded its time budget without establishing a robust alternative — no nearby setup was validated. Right now price sits at $211.58, about 1.2% above the 9-day average at $209.15, with the RSI condition already met and a MACD cross still pending, making this a genuine watch-list idea rather than a live trade. With realized annualized volatility of roughly 38–55% and kurtosis of 26.6, a 2.3% stop is tight for this name. **Conviction breakdown:** Thesis support 65 (approval is real, cash is ample); Fundamentals trend 20 (burn widening, no revenue, 20th percentile free cash flow among Health Care peers); Trade readiness 25 (no setup established after the bounded search timed out); Trigger proximity 60 (price is about 1.2% from the entry zone, RSI condition met); Risk quality 40 (tight bracket and clear invalidation, but volatility can blow through the stop).

Trade now

RVMD closed at $211.58, and the idea's dip-buy setup is close to but not yet in its entry window. The strategy calls for a pullback after the pop: price at or below the 9-day average, currently $209.15 (about 1.1% under the last close), with that 9-day average still above the 20-day at $202.83 — a condition already met with a 3.1% cushion. RSI must hold above 40, which it does comfortably at 63.0, and a MACD signal-line cross must print on the same bar; the MACD line sits at 7.71 but has not crossed. In short, the trend structure is bullish, but the dip has not arrived. If the entry triggers near the 9-day average around $209, the risk controls are tight. The fixed stop is a 2.3% loss, roughly $204 from a $209 entry, with a backstop below second-tier support at $161.95, and a take-profit at 4.6% (near $219) or at the nearest resistance print of $194.38 if reached first from below. The percentage-based stop and target imply an effective reward-to-risk of about 2:1 on the fixed bracket. Position sizing is 2.3% risk per trade, capped at 25% of the account — respect that cap on a stock this volatile, with realized annualized volatility of roughly 38–55%. What "wait" means concretely: do nothing while price sits above $209 and no MACD cross prints. The most likely trigger path is a modest 1–2% profit-taking dip that tags the 9-day average alongside a fresh MACD bullish cross — that alignment, not the FDA news itself, starts the trade. A deeper flush toward $200 or the $190 support shelf would…

Scores

• Conviction score breakdown: 42
• Thesis support: 65
• Trade readiness: 25
• Risk quality: 40
• Trigger proximity: 60
• Fundamentals trend: 20

Watch items

• RVMD — Price vs 9-day EMA
• RVMD — MACD (12,26,9) signal cross
• RVMD — RSI (14)
• RVMD — Daily close vs $200 support
• RVMD — RSI (14) breakdown
• RVMD — RSI (14) overbought exit
• RVMD — Price
• RVMD — EMA (9) crossed above EMA (20)
• RVMD — RSI (14) above 40
• RVMD — MACD (12,26,9) crossed above MACD (12,26,9)
• RVMD — RSI (14) above 72
• RVMD — Price below EMA (9)